

**AHCCCS**

**Pharmacy and Therapeutics Committee Meeting Minutes**

January 16, 2018

12:00PM- 5:00 PM

701 E. Jefferson Phoenix, AZ 85034- Gold Room- 3<sup>rd</sup> Floor

**Members Present:**

Loann Nguy  
Yvonne Johnson  
Dan Lindell  
Robert Marotz  
Jose Arindaeng  
Stephen Borodkin  
Cindy Komar  
Mohammed Ramadan  
Kelly Flannigan  
Sandy Brownstein  
Shawn McMahan  
Joanna Kowalik  
Raul Romero

**AHCCCS Staff:**

Sara Salek  
Suzi Berman  
Lauren Prole  
Robin Davis  
Chaz Longwell

**Magellan Medicaid Admin:**

Lara Frick  
Christopher Andrews

**Members Absent:**

Otto Uhrik

**WELCOME AND INTRODUCTIONS: SARA SALEK, M.D., CHIEF MEDICAL OFFICER, AHCCCS**

---

1. Dr. Sara Salek called the meeting to order at 12:03 PM and welcomed committee members, staff, and guest presenters.
    - a. P&T Minutes from October 12, 2017 were reviewed.
      - i. Motion made to approve meeting minutes by Joanna Kowalik
      - ii. Motion seconded by Dan Lindell
      - iii. 9 present members voted in favor of approving the minutes
      - iv. No present committee members opposed
      - v. One present committee member abstained.
    - b. AHCCCS P&T Operational Policy Overview
- 

**HIV/PrEP Presentation by Dr. Ann Khalsa**

---

1. Journal articles will be sent to committee members for review. This subject will be put to a vote in the April 2018 meeting.
2. The presentation will be available on the AHCCCS website under the Pharmacy Section under Pharmacy & Therapeutics Committee, Agendas and Meetings, January 16, 2018.

**SUPPLEMENTAL REBATE CLASS REVIEWS**

---

**Supplemental Rebate Class Review:**

1. Inhaled Glucocorticoids
    - a. Clinical review: Lara Frick, PharmD: Magellan
    - b. Pharma Testimony: None
- 

**Executive Session – Closed to the Public**

---

**Preferred Drug Recommendation to the AHCCCS Drug List and/or the AHCCCS Behavioral Health Drug List for the following classes:**

1. Inhaled Glucocorticoids
  - a. The committee members voted unanimously on the below recommendations for preferred products. No committee members opposed or abstained.
    - i. Single Agent Products
      1. Asmanex

2. Flovent HFA
  3. Pulmicort Flexhaler (new addition to PDL)
  4. Pulmicort Respules
    - a. Recommendation is to remove prior authorization for children under the age of 4 for Pulmicort Respules.
  5. QVAR has been discontinued by the manufacturer as of February 2018. The product is only available while supplies last.
- ii. Combination Products
    1. Advair Diskus
    2. Advair HFA- only for ages 4-12
    3. Dulera
    4. Symbicort
2. Cytokine and CAM Antagonists – Postponed from October 2017
    - a. The committee members voted unanimously on the below recommendations for preferred products. No committee members opposed or abstained.
      - i. Enbrel Kit, Syringe and Pen
      - ii. Humira Kit and Humira Pen Kit
3. Long Acting Opioid Agonists
    - a. The committee members voted unanimously on the below recommendations for preferred products. No committee members opposed or abstained.
      - i. Remove Nucynta ER as a preferred agent
      - ii. Add Tramadol ER as a preferred agent

**NEW DRUG REVIEWS: NON-SUPPLEMENTAL REBATE CLASS: LARA FRICK, PHARM D, MAGELLAN**

---

1. The following new drugs were reviewed for the Non-Supplemental Rebate Class
  - a. Gocovri- amantadine
    - i. Recommendation is to not add this drug to the AHCCCS Drug list. Gocovri is available through Prior authorization based on medical necessity.
      1. All committee members voted in favor of the recommendations.
      2. No committee members voted against the recommendations.
      3. No committee member abstained.
  - b. Vyzulta- latanoprostene bunod
    - i. Recommendation is to not add this drug to the AHCCCS Drug list. Vyzulta is available through Prior authorization based on medical necessity.

1. All committee members voted in favor of the recommendations.
  2. No committee members voted against the recommendations.
  3. No committee member abstained.
- c. Solosec- secnidazole
- i. Recommendation is to not add this drug to the AHCCCS Drug list. Solosec is available through Prior authorization based on medical necessity.
    1. Nine committee members voted in favor of the recommendation.
    2. One committee members voted against the recommendation.
    3. No committee member abstained.
- d. Xhance- fluticasone propionate
- i. Recommendation is to not add this drug to the AHCCCS Drug list. Xhance is available through Prior authorization based on medical necessity.
    1. All committee members voted in favor of the recommendations.
    2. No committee members voted against the recommendations.
    3. No committee member abstained.

**OPEN COMMENTS**

---

**2018 MEETING DATES**

---

April 17, 2018

July 17, 2018

October 22, 2018

**ADJOURNMENT**

---

The meeting adjourned at 3:32 PM

Minutes recorded by Robin Davis

*Suzanne Berman*

Suzi Berman, RPh

Director of Pharmacy Services

April 17, 2018

Date